Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN Poll

 More »
Oct 31, 2011

Royalty/Revenue Monetization

Do you think entering royalty and revenue monetization transactions is a good strategy for a cash-strapped firm?

Yes
 
  58.8%
No
 
  23.5%
Undecided
 
  17.6%

Suggest a Poll
More Polls » View Results »

A relatively small but growing number of drug developers are monetizing their royalties/revenues by selling off all or part of these income streams to investors. If done prior to launch, these deals can protect against downside risk of the product not being a commercial success. But royalty/revenue monetization is still a relatively expensive source of capital, compared to raising conventional debt, if that is a possibility. Click here for more pros and cons. The amount of capital provided for royalty/revenue monetization deals over the past five years has doubled since between 2000 and 2005. Tell us if you would tap into this source of capital.

Related Content

GEN News Highlights

MORE RELATED GEN NEWS HIGHLIGHTS

Insight & Intelligence™

MORE RELATED INSIGHT & INTELLIGENCE™

GEN Articles

MORE RELATED GEN ARTICLES

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

GEN’s Hall of Shame

Will you be voting for any of the candidates on GEN’s Hall of Shame list in the next election?

Suggest a Poll